23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Praxis Precision Medicines, Inc. › 2025-2026

Praxis Precision Medicines, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Praxis Precision Medicines, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 303Asset managers, any item
  • 2,128Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 5 items on Praxis Precision Medicines, Inc.’s Form 8-K, filed June 12, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (14.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Praxis Precision Medicines, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Praxis Precision Medicines, Inc.

These tallies are Praxis Precision Medicines, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Praxis Precision Medicines, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Gregory Norden 24,597,327---- 310,9371,815,967 99%Passed (calculated)—
Elect Director: Marcio Souza 24,771,396---- 136,8681,815,967 99.5%Passed (calculated)—
Elect Director: William Young 21,293,535---- 3,614,7291,815,967 85%Passed (calculated)—
2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm 26,667,37639,28517,570 --0 99.9%Approved—
3. Advisory Vote on Executive Compensation 24,054,017824,31829,929 --1,815,967 97%Approved—

Source: Praxis Precision Medicines, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the Praxis Precision Medicines, Inc. 2025-2026 meeting

303 asset managers disclosed a vote on at least one Praxis Precision Medicines, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Gregory Norden

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 24,597,327WITHHELD: 310,937
Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Gregory Norden

Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: Gregory Norden”): 24,597,327 for, 310,937 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 9,284,367 for, 53,032 withheld.

FOR
FOR: 9,284,367WITHHOLD: 53,032
Largest asset managers voting on “To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respec” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,028,4720 03,755For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable69,2410 018,560Mixed
American Century86,9620 00For
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,7220 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Elect Director: Marcio Souza

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 24,771,396WITHHELD: 136,868
Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Marcio Souza

Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: Marcio Souza”): 24,771,396 for, 136,868 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 9,304,326 for, 33,073 withheld.

FOR
FOR: 9,304,326WITHHOLD: 33,073
Largest asset managers voting on “To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respec” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,029,8710 02,356For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable87,8010 00For
American Century86,9620 00For
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,7220 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Elect Director: William Young

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 21,293,535WITHHELD: 3,614,729
Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William Young

Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: William Young”): 21,293,535 for, 3,614,729 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 8,404,448 for, 932,942 withheld, 9 abstained.

FOR
FOR: 8,404,448ABSTAIN: 9WITHHOLD: 932,942
Largest asset managers voting on “To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respec” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard1,965,6250 966,593For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,083,1210 022,477For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust11,0890 0129,811Mixed
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS00 0119,129Withhold
Equitable69,2410 018,560Mixed
American Century00 086,962Withhold
Goldman Sachs1,1580 063,599Withhold
TIAA58,6740 00For
Jackson National16,2940 029,244Mixed
Aberdeen00 044,768Withhold
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica00 033,722Withhold
MERIDIAN FUND INC00 028,070Withhold
Lincoln Financial19,3660 05,884Mixed
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 16 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 24,054,017AGAINST: 824,318

Prior year: 60.7% for (June 26, 2025 meeting) ▲ 36.0 pts

Details: description as filed, official tally, votes by 303 asset managers

Description as filed by funds: To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.

Praxis Precision Medicines, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 24,054,017 for, 824,318 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 91 asset managers voting on “To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed ” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,032,2261 00For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable87,8010 00For
American Century086,962 00Against
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco038,541 00Against
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,7220 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Fund voting reports, all 91 managers: 9,207,172 for, 134,080 against, 147 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 239 asset managers voting on “To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed ” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson6,677,4505,542 00For
Fidelity2,102,4680 00For
Orbis Allan Gray Ltd2,077,4470 00For
PERCEPTIVE ADVISORS LLC1,752,5270 00For
BlackRock911,0135,632 00For
State Street848,9564,850 00For
T. Rowe Price839,6740 00For
GEODE CAPITAL MANAGEMENT, LLC650,8800 00For
DRIEHAUS CAPITAL MANAGEMENT LLC643,0670 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.585,5970 00For
DEERFIELD MANAGEMENT COMPANY, L.P.554,7220 00For
Cormorant Asset Management, LP347,7240 00For
Hood River Capital Management LLC346,9870 00For
Vivo Capital, LLC338,8950 00For
RA CAPITAL MANAGEMENT, L.P.335,1320 00For
Soleus Capital Management, L.P.331,9810 00For
FRANKLIN ADVISERS INC271,2570 00For
PICTET ASSET MANAGEMENT SA264,1170 00For
AustralianSuper Pty Ltd0227,786 00Against
Charles Schwab216,4510 00For
Vanguard209,8750 00For
Northern Trust201,5851,018 00For
Aberdeen172,4840 00For
ORBIMED ADVISORS LLC165,5100 00For
Woodline Partners LP157,8860 00For

Institutional-manager reports, all 239 managers: 22,941,662 for, 644,159 against, 882 abstained, 102 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 26,667,376AGAINST: 39,285

Prior year: 100.0% for (June 26, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Praxis Precision Medicines, Inc.’s own tally for this item (“2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm”): 26,667,376 for, 39,285 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 9,337,253 for, 147 abstained.

FOR
FOR: 9,337,253ABSTAIN: 147
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,032,2280 00For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable87,8010 00For
American Century86,9620 00For
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,7220 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Largest Praxis Precision Medicines, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 27,859,514 shares outstanding at the time of that meeting.

Fund voting reports: top Praxis Precision Medicines, Inc. shareholders by shares voted on “To approve, on an advisory (non-binding) basis, the compensation of the named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 8.07%
2Vanguard 7.29%
3BlackRock 4.23%
4JANUS INVESTMENT FUND 3.97%
5T. Rowe Price 2.01%
6State Street 1.20%
7Charles Schwab 0.78%
8Manager Directed Portfolios 0.76%
9Bridge Builder Trust 0.51%
10FRANKLIN STRATEGIC SERIES 0.43%
Institutional-manager reports: top Praxis Precision Medicines, Inc. shareholders by shares voted on “To approve, on an advisory (non-binding) basis, the compensation of the named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 23.99%
2Fidelity 7.55%
3Orbis Allan Gray Ltd 7.46%
4PERCEPTIVE ADVISORS LLC 6.29%
5BlackRock 3.29%
6State Street 3.06%
7T. Rowe Price 3.01%
8GEODE CAPITAL MANAGEMENT, LLC 2.34%
9DRIEHAUS CAPITAL MANAGEMENT LLC 2.31%
10ADAGE CAPITAL PARTNERS GP, L.L.C. 2.10%

Reported Praxis Precision Medicines, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Praxis Precision Medicines, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Janus Henderson Group2,763,859 9.92%Proxy statement (DEF 14A), table as of April 15, 2026
BlackRock2,324,929 8.35%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)2,160,943 7.76%Form 13F, quarter ended March 31, 2026
Entities affiliated with Perceptive Advisors1,995,986 7.16%Proxy statement (DEF 14A), table as of April 15, 2026
Perceptive Advisors LLC1,995,986 7.16%Schedule 13G, filed February 17, 2026
Baker Bros. Advisors LP1,753,198 6.29%Schedule 13G, filed May 15, 2026
Entities affiliated with Point721,569,309 5.63%Proxy statement (DEF 14A), table as of April 15, 2026
ORBIS INVESTMENT MANAGEMENT LTD1,526,680 5.48%Schedule 13G, filed August 14, 2026
Vanguard Group1,460,933 5.24%Form 13F, quarter ended March 31, 2026
Morgan Stanley889,889 3.19%Form 13F, quarter ended March 31, 2026

Percentages above are of 27,859,514 shares outstanding, as reported by Praxis Precision Medicines, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Praxis Precision Medicines, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 303 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,128 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non-binding) basis, the compensation of the named executive… — Praxis Precision Medicines, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Praxis Precision Medicines, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Praxis Precision Medicines, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Praxis Precision Medicines, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Praxis Precision Medicines (PRAX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/praxis-precision-medicines-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.